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Abstract
The delta family of ionotropic glutamate receptors consists of glutamate d1 (GluD1) and glutamate d2 (GluD2) receptors.
While the role of GluD2 in the regulation of cerebellar physiology is well understood, the function of GluD1 in the central
nervous system remains elusive. We demonstrate for the first time that deletion of GluD1 leads to abnormal emotional
and social behaviors. We found that GluD1 knockout mice (GluD1 KO) were hyperactive, manifested lower anxiety-like
behavior, depression-like behavior in a forced swim test and robust aggression in the resident-intruder test. Chronic
lithium rescued the depression-like behavior in GluD1 KO. GluD1 KO mice also manifested deficits in social interaction. In
the sociability test, GluD1 KO mice spent more time interacting with an inanimate object compared to a conspecific
mouse. D-Cycloserine (DCS) administration was able to rescue social interaction deficits observed in GluD1 KO mice. At a
molecular level synaptoneurosome preparations revealed lower GluA1 and GluA2 subunit expression in the prefrontal
cortex and higher GluA1, GluK2 and PSD95 expression in the amygdala of GluD1 KO. Moreover, DCS normalized the lower
GluA1 expression in prefrontal cortex of GluD1 KO. We propose that deletion of GluD1 leads to aberrant circuitry in
prefrontal cortex and amygdala owing to its potential role in presynaptic differentiation and synapse formation.
Furthermore, these findings are in agreement with the human genetic studies suggesting a strong association of GRID1
gene with several neuropsychiatric disorders including schizophrenia, bipolar disorder, autism spectrum disorders and
major depressive disorder.
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Introduction
The delta family of ionotropic glutamate receptors (iGluRs)
consists of the glutamate d1 (GluD1) and glutamate d2 (GluD2)
receptors which share ,60% homology [1]. GluD2 is selectively
expressed at the parallel fiber-Purkinje cell (PF-PC) synapse in the
adult cerebellum [2–4]. Deletion of GluD2 leads to severely
reduced PF-PC synapses and abrogated long-term depression
together with ataxia and impaired motor learning [5]. Moreover,
recent studies have established that the N-terminal domain (NTD)
of GluD2 is necessary and sufficient for induction of presynaptic
differentiation and synapse formation [6–8]. GluD1 is highly
expressed in the inner hair cells of the organ of Corti [9,10].
Deletion of GluD1 leads to a deficit in high frequency hearing in
mice [10]. In the central nervous system (CNS), GluD1 is
expressed diffusely throughout the forebrain during early devel-
opment [1], [11] however its functional significance remains
elusive. GluD1 knockout mice (GluD1 KO) have normal learning
in the water maze test and intact hippocampal long-term
potentiation [10]. In vitro studies indicate that GluD1, similar to
GluD2, may induce presynaptic differentiation and synapse
formation [6,8,12,13].
The strongest evidence of potential involvement of GluD1 in
regulating neural circuitry comes from human genome-wide
association studies. Genetic association studies have established
the GRID1 gene, which codes for GluD1, as a strong candidate
gene for schizophrenia, bipolar disorder, and major depressive
disorder [14–21]. Copy number variation studies have also
implicated GRID1 in autism spectrum disorder (ASD) [22–24].
In addition, GRID1 gene is localized to the 10q22–q23 genomic
region which is a site for recurrent deletions associated with
cognitive and behavioral abnormalities [25,26].
In this study we performed behavioral characterization of the
GluD1 KO mice and found remarkable features including
hyperactivity, lower anxiety-like behavior, depression-like behav-
ior, hyperaggression and deficits in social interaction in the GluD1
KO. Additionally we found changes in synaptoneurosomal
expression of synaptic proteins, including iGluR subunits, in the
prefrontal cortex and amygdala of GluD1 KO. The synaptoneur-
osomal abnormalities further support a potential role of GluD1 in
the regulation of synapse via its proposed effect on presynaptic
differentiation and synapse formation [6,8,12,13]. Overall, our
results underscore the importance of GluD1 in development of
normal neural circuitry in brain regions that regulate emotional
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appearance of characteristic features of neuropsychiatric disorders.
Materials and Methods
Ethics statement
All experimental protocols were approved by the Creighton
University Institutional Animal Care and Use Committee Policies
and Procedures. In this study strict measures were taken to
minimize pain and suffering to animals in accordance with the
recommendations in the Guide for Care and Use of Laboratory
Animals of the National Institutes of Health. The IACUC
protocols for these studies were 0893 and 0865.
Generation and genotyping of GluD1 knockout mice
GluD1 KO mice were obtained from Dr. Jian Zuo, St. Jude’s
Children’s Hospital [10]. These mice had been generated by
creating a targeting construct that deleted exons 11 and 12 of the
GluD1 gene (GRID1). The targeted disruption ensured removal of
three of the four transmembrane domains of the GluD1 receptor
and introduced a frameshift after exon 12. In the PCR analysis no
220 bp wildtype bands (in the deleted region) were detected in the
homozygous GluD1 KO mice. All mice analyzed were from a
mixed background of 129/SvEv and C57BL/6 in the F2 to F6
generations [10].
Genotyping was done as previously described [10]. The primers
used for the reaction were as follows: a pair of primers from the
deleted region of GluD1; 59GCAAGCGCTACATGGACTAC 39
and 59GGCACTGTGCAGGGTGGCAG 39 and a pair of
primers from the targeting vector; 59CCTGAATGAACTGCAG-
GACG 39 and 59CGCTATGTCCTGATAGCGATC 39.
Mouse husbandry
Wildtype (WT), GluD1 heterozygous and GluD1 KO male
mice, aged 8 weeks were either group housed (4–5 mice) or single
housed (as per the requirements of the test) in the animal house
facility at a constant temperature (2261uC) and a 12-hr light-dark
cycle with free access to food and water. Behavioral testing was
performed between 9:00 a.m and 4:00 p.m. The study did not
involve using female mice to avoid the confounding effects of the
estrus cycle on behavioral and neurochemical measures. The WT,
GluD1 heterozygous and GluD1 KO mice were obtained from
previously genotyped parent cages.
Behavioral testing
Behavioral testing was performed between 9:00 a.m and 4:00
p.m. As per the requirements of the tests, mice were handled for 3
days to acclimatize them to the experimenter before subjecting
them to the experimental procedures. Each day the experimenter
picked up each animal and the animal was allowed to explore the
experimenter’s hand for 2 min. All experimental animals were
placed in the experimental room at least 60 min before beginning
any experimental protocol. Unless indicated otherwise, all
experimental environments were thoroughly cleaned with 70%
ethanol between trials which was given time to dry away. All
behavioral procedures were video-recorded and scored by a scorer
blind to the genotype of the animal via a random coding system of
the video files.
Lithium treatment
Chronic lithium treatment was conducted as previously
described [27]. This protocol has been shown to maintain trunk
blood level of lithium within the human therapeutic level (0.4–
1.2 mM). We measured the blood lithium concentration at the end
of the experiments and found that they were within this stipulated
range (0.7–1.0 mM) (performed at Creighton University Medical
laboratory, Omaha, NE, USA). Lithium concentration was
measured using the Thermo Scientific Infinity Lithium reagent,
Rockford, IL, USA. The assay is based on change in absorbance
with binding of lithium to substituted porphyrin compound at
alkaline pH. Absorbance was measured using Beckman Coulter
DXC Synchron, Brea, CA, USA. WT and GluD1 KO mice were
fed lithium carbonate chow (2.4 g/kg, Bioserve, Frenchtown, NJ,
USA) or control chow identical to lithium carbonate chow with the
exception of lithium salt for 4 weeks. Due to the side effects of
polyuria and polydipsia the cage bedding and water bottles were
changed twice a week. Mice were also supplied with 0.9% NaCl in
addition to tap water to supplement for possible electrolyte
imbalance. We measured the body weight and food consumption
in a small group of animals during the lithium treatment. The
body weight did not decrease over the course of lithium diet and
the food consumption was also similar to the regular diet. Mice
were then subjected to the open field, forced swim and the
resident-intruder test, the procedures for which have been
described later in the methods section.
D-Cycloserine (DCS) treatment
There were four groups of mice, WT saline, GluD1 KO saline,
WT DCS and GluD1 KO DCS. DCS (Sigma-Aldrich (C6880); St
Louis, MO, USA) was dissolved in 0.9% saline. Freshly dissolved
DCS was used for experiments. We used a dose of DCS that has
previously been shown to be efficacious in social behavior in mice
[28,29]. Mice were administered a single dose of 320 mg/kg DCS
in 0.9% saline (80–100 ml) or 0.9% saline (90 ml) intraperitoneally,
20 min prior to beginning the sociability/social novelty test. The
sociability test and the test for social novelty were performed after
DCS treatment. The procedures for the sociability test and the test
for social novelty are described later in the methods section.
Test for vision
To test normal vision in GluD1 KO we performed a qualitative
test. The mice were picked up by the tail and slowly lowered to a
wire cage lid. Vision (score of 1) was reflected in an animal’s
extending its forepaws and attempting to grip the lid just before
contact with the surface. If the mouse failed to exhibit this
behavior it was scored as blind (score of 0). Since all animals in
both genotypes WT and GluD1 KO received a score of 1 no
statistical analysis was performed.
Test for olfaction
Hide the cookie test was performed to test olfaction [30]. Two
days before the test, mice were acclimatized to the food stimulus; a
mini cookie from Teddy Grahams (Nabisco, Hanover, New Jersey).
18–24 hrs before the test, mice were fasted with freeaccessto water.
The mouse to be tested was then placed in a clean cage with 3 cm
deep bedding and allowed to acclimate to the cage for 5 min. The
mouse was then transferred to an empty cage. In the cage
containing the bedding, the food stimulus was buried 1 cm beneath
the bedding in a random corner of the cage. The bedding surface
was made smooth. The mouse was reintroduced into the cage and
the latency to find the food stimulus was recorded. In case a mouse
failed to find the buried food stimulus, the mouse was allowed to
explore the cage for 15 min and the latency was scored as 900 sec.
Open field test
The open field test was performed as previously described [31].
Spontaneous locomotor activity was recorded in an open field
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bottom. White light of 300–330 lux intensity was used to evenly
illuminate the entire open field arena. The number of times and
total time the mouse entered the central four squares (central field
penetration) as well as the total number of line crosses made by the
mouse in the 15 min interval were tallied and expressed as
cumulative line crosses during the 15 min interval. Scoring was
done by an experimenter blind to the genotype of the mice.
Marble burying test
The marble burying test was performed as previously described
[32] with minor modifications. Anxiety-like behavior was assessed
with the marble burying test using a square 25625 cm arena with
the home cage bedding to a height of 5 cm. White light of 300–
330 lux intensity was used to evenly illuminate the entire arena of
the marble burying test. 36 dark colored marbles 1.5 cm in
diameter were placed 5 cm apart. The test mouse was placed in
the same corner of the open field arena and left in the arena for
30 min. At the end of the 30 min the mouse was taken out and the
number of marbles buried was counted. If two-thirds of a marble
was buried inside the bedding it was counted as buried otherwise
non-buried. The marble burying test is based on the observation
that mice experiencing greater anxiety-like behavior would bury
greater number of marbles [32].
Elevated plus maze
The elevated plus maze was constructed and conducted as
previously described [33] with modifications for time similar to
[31]. The apparatus was made of plastic material and was elevated
to a height of 40 cm above the ground. Each arm of the plus maze
was 30 cm in length and 5 cm in width. Additionally, the closed
arms had wall enclosures that were 15.25 cm high. The central
platform was a square of 565 cm. Light intensity around the maze
was set at 300–330 lux. Mice were placed on the elevated plus
maze for 15 min. Mice were placed on the elevated plus maze
facing the open arm opposite to the experimenter. Arm location
was recorded with an elevated video camera. The animals were
videotaped for 15 minutes. The number of entries and the time
spent in the open and closed arms were recorded over the entire
duration of the test.
Forced swim test
The forced swim test measures depression-like behavior in mice
[34] with modifications. Mice were placed in a glass cylinder
13 cm diameter X 24 cm high, filled with 10 cm high water
(2262uC), for a period of 5 min. Water was changed between
subjects. All test sessions were recorded by a video camera
positioned in front of the glass cylinder. Videotapes were
subsequently scored by an observer blind to the genotype of the
mice. Mice were judged immobile when they remained floating
passively in the water, with minor movements to keep their heads
above the water. The videos were scored for total duration of
immobility and latency to immobility. Latency to immobility is
defined as the duration of time from the beginning of the test
session, to the appearance of the first 3 sec immobile event.
Sucrose preference test
The sucrose preference test was conducted as previously
described [35] with minor modifications. Mice were individually
housed for this test. During the test, mice were given for 24 hr, a
free choice between 1% sucrose in one bottle and tap water in
another. To avoid the possible effects of side preference in drinking
behavior, the position of the bottles was interchanged after 12 hr.
The mice were not subjected to previous food or water deprivation
prior to the test. Water and sucrose consumption was calculated in
both groups by weighing the bottles. The preference for sucrose
was calculated as a percentage of sucrose solution consumed of the
total amount of liquid drunk.
Resident-intruder test
The resident-intruder test was performed as previously
described [36] with minor modifications. The resident animals
were singly housed for three weeks and the last one week prior to
conducting the test no cage change was done. A WT mouse
(intruder) was introduced into the home cage of the singly housed
resident animal. The grid wire holding the feed and the water
bottle was removed; the cotton in the cage was also removed while
conducting the test. All the resident animals weighed 4–5 g more
than the intruder animals. The two mice were left to interact for
10 min. Each intruder mouse was only used once. The interaction
between the two mice was videotaped and scored later for attack
latency and frequency of attacks with the scorer being blind to the
genotype of the mice. Attack latency is defined as the time taken
for the resident mouse to initiate the first attack.
Sociability test/Preference for social novelty
The procedure for the social interaction and social novelty test
were performed as previously described [37,38] with minor
modifications. The experiment was conducted in a room with a
light intensity of 300–330 lux. The social interaction chamber is a
three chambered apparatus made of clear Plexiglas. Doorways
built into the two dividing walls controlled access to the side
chambers. Each of the three chambers was 20 cm length
640.5 cm width 622 cm high. In the sociability test, the
experimental mouse was subjected to a 5 min acclimation period
in the middle chamber with doors to both side chambers closed.
This was done in the presence of an unfamiliar adult male
(Stranger 1) in one of the chambers and an inanimate object in the
other chamber. A transparent plastic container with holes was
used to enclose the Stranger 1 mouse. The other chamber
contained an empty container of the same size (referred to as
inanimate object). A weighted plastic cup was placed on top of
each plastic container to prevent the subject from climbing to the
top. Location of the stranger mouse and the inanimate object was
alternated between the two-side chambers on consecutive sessions.
During the sociability test doors to the chambers on either side
were opened and the experimental mouse was allowed to explore
the three chambers for 10 min. A circle with a 1 cm radius was
marked around the periphery of the plastic container. The
duration the experimental mouse spent within this circle
interacting with the inanimate or Stranger 1 containing plastic
container was recorded. The percent time interacting with
Stranger 1 was reported as; time interacting with Stranger 1/
[(time interacting with the inanimate object) + (time interacting
with Stranger 1)]*100. Subsequently the same experimental mouse
was subjected to the test for social novelty, beginning with the
experimental mouse being acclimatized to the middle chamber for
10 min in the presence of the two stranger mice, one on either
side, with the second unfamiliar mouse being a new stranger
mouse (Stranger 2) placed in the opposite side, which was
previously empty during the sociability test with the doors on
either side of the middle chamber to the side chambers being
closed. During the test for social novelty, the doors on either side
were raised open and the experimental mouse was allowed to
explore all the three chambers for 10 min. The duration the
experimental mouse spent exploring the circle around plastic
container containing Stranger 1 or Stranger 2 was recorded. The
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interacting with Stranger 2/[(time interacting with Stranger 1 +
time interacting with Stranger 2)]*100. All the stranger mice used
for the experiment were WT mice. The entire procedures were
video-taped and scored later by a person blind to the genotype of
the mice.
mRNA expression analysis
For mRNA expression analysis 15 day old naive WT and
GluD1 KO mice were anesthetized using isoflurane anesthesia.
Mice were then decapitated and thereafter all experimental
procedures were conducted on ice. The brain was dissected out,
the amygdala, prefrontal cortex and hippocampi were crudely
dissected out and the freshly dissected amygdala, prefrontal cortex
and hippocampi were put into TRIzol reagent (1 ml TRIzol
reagent per 50–100 mg of tissue) and homogenized. Phase
separation was achieved by addition of 0.2 ml of chloroform
and centrifugation at 12,0006g for 15 min at 2–8uC. For RNA
precipitation, the aqueous phase was transferred into a fresh tube
and 0.5 ml isopropyl alcohol was added. The samples were
incubated for 10 min and centrifuged at 12,0006g for 10 min at
2–8uC. RNA pellet was washed once with 75% ethanol, briefly
dried and dissolved in DEPC water.
The primers used for the reaction were as follows: GluD1
forward 59 ACCTCCTGGAATGGGATGAT, GluD1 reverse 59
CCTCAGGCTTCTTGATGAGG, b-actin forward 59AATTT-
CTGAATGGCCCAGGT, b-actin reverse 59 TGTGCACTTT-
TATTGGTCTCAA. For RT-PCR, 3 mg RNA was purified from
the amygdala, hippocampus and the prefrontal cortex of postnatal
day 15 WT and GluD1 KO mice and subjected to DNAse
treatment and was thereafter reverse transcribed into cDNA in a
10 ml reaction and the cDNA thus obtained was subjected to a
conventional RT-PCR . In each case, RNA samples were verified
as free of DNA contamination by running RT-PCR negative
control lacking reverse transcriptase. From the 10 ml cDNA, 5 ml
was used for PCR reaction with GluD1 primers and 5 ml was used
for PCR reaction with b-actin primers. For the PCR, total of
32 cycles were employed with annealing at 55uC and extension at
72uC. 12 ml of each sample’s PCR product was separated by 2%
agarose gel electrophoresis and the gels were imaged using a UV
image analyzer.
Synaptoneurosome preparation and western blot
analysis
For synaptoneurosomal preparation 45–50 day old naive WT
and GluD1 KO mice were anesthetized using isoflurane
anesthesia, mice were then decapitated and thereafter all
experimental procedures were conducted on ice. The amygdala
and prefrontal cortex were crudely dissected out and put into
synaptoneurosomal buffer at 4uC. Thereafter, the fresh tissue,
amygdala and prefrontal cortex were used for synaptoneurosome
preparation and western blotting.
The freshly isolated amygdala and prefrontal cortex from WT
and GluD1 KO mice were homogenized in synaptoneurosome
buffer (10 mM HEPES, 1 mM EDTA, 2 mM EGTA, 0.5 mM
DTT, 10 mg/ml leupeptin, and 50 mg/ml soybean trypsin
inhibitor, pH 7.0) as previously described [39], additionally
containing 5 mg/ml pepstatin, 50 mg/ml Aprotonin and
0.5 mM phenylmethanesulfonylfluoride (PMSF). From this step
forward the homogenate was kept ice-cold at all times to minimize
proteolysis throughout the isolation procedure. The homogenate
was diluted further with the same volume of synaptoneurosome
buffer and briefly and gently sonicated delivering 3 pulses using an
output power of 1 Sonic dismembrator Model 100 (Fischer
Scientific, NJ, USA). The sample was loaded into a 1.0 ml Luer-
lock syringe (BD syringes) and filtered twice through three layers of
a pre-wetted 100 mm pore nylon filter CMN-0105-D (Small Parts
Inc., Logansport, IN, USA) held in a 13 mm diameter filter holder
XX3001200 (Milipore, MA). The resulting filtrate was loaded into
a 1 ml Luer-lock syringe and filtered through a pre-wetted 5 mm
pore hydrophilic filter CMN-0005-D (Small Parts Inc., Logan-
sport, IN, USA) held in a 13 mm diameter filter holder. The
resulting filtrate was centrifuged at 10006g for 10 min. The pellet
obtained corresponded to the synaptoneurosome fraction. Isolated
synaptoneurosomes were resuspended in 75 ml of buffer solution
containing 0.32 M sucrose, and 1 mM NaHCO3 (pH 7.0).
For western blotting synaptoneurosomes prepared from 45–50
day old naive WT and GluD1 KO mice were loaded on 10%
Sodium dodecyl sulfate gel in equal amount (15 mg/well). The
samples were run at 114 volts for a duration of 1 hr. Gels were
transferred to nitrocellulose membrane (GE Healthcare, Piscat-
away, NJ, USA), a wet transfer was carried out. The voltage for
transfer was kept at 114 volts and duration for which transfer was
carried out was 1 hr 15 min. Electrophoresis and transfer
apparatuses used were the Biorad mini protean tetra cell, from
Bio-Rad Laboratories, Inc., Hercules, California, USA. Transfer
was followed by blocking with 5% milk in Tris-buffered Saline
with 1% Tween 20 (TBST) for 1 hr at room temperature. The
primary antibodies GluA1 (Millipore, Billerica, MA, USA),
1:1500; GluA2 (Millipore), 1:2000; GluN2B (Millipore), 1:1000;
GluK2 (Abcam, Cambridge, MA, USA), 1:1000; vesicular
glutamate transporter 2 (vGluT2) (Millipore), 1:1000; glutamic
acid decarboxylase 67 (GAD67) (Millipore), 1:1000; postsynaptic
protein density 95 (PSD95) (Affinity Bioreagents, CO, USA),
1:2500 and Synaptophysin (Zymed, Carlsbad, CA, USA), 1:2500
were used and kept overnight for incubation at 4uC followed by
washing and were incubated with horse-radish peroxidase
conjugated anti-rabbit secondary antibody 1:5000; (Cell Signaling
Technology, Danvers, MA, USA) for 1 hr at room temperature
followed by washing with TBST. Blots were developed using
enhanced chemiluminescent (ECL) Plus Western Blotting Detec-
tion System kit RPN2132 (GE Healthcare, Piscataway, NJ, USA)
and images were taken using Precision Illuminator Model B95
(Imaging Research Inc., Germany) with a MTI CCD 72S camera
and analyzed using MCID Basic software version 7.0 (Imaging
Research, St. Catharines, ON, Canada). The X-ray film processor
used was model- BMI No 122106 (Brown’s Medical imaging,
Omaha, NE, USA). For analysis of protein expression, first, the
optical density of each sample was normalized to b-actin.
Thereafter, the optical density was normalized to the mean of
the WT samples. The average 6 SEM of optical densities of
GluD1 KO samples, that were normalized to WT mean, are
represented as Ratio (KO/WT) 6 SEM. The P values were
calculated from optical densities of WT and GluD1 KO samples
normalized to the WT mean.
Statistics
Data were analyzed using Student’s unpaired t-test with Welch’s
correction (open field test, marble burying test, elevated plus maze
test, forced swim test, sucrose preference test, resident-intruder
test, sociability test, social novelty test, molecular changes in the
amygdala and prefrontal cortex) or two-way ANOVA (analysis of
variance) with Bonferroni’s post-hoc test (lithium effect on open
field test, forced swim test and resident-intruder test and DCS
effect on sociability and social novelty test and protein expression
in amygdala and prefrontal cortex). Differences were considered
significant if P#0.05. Prism 4 (GraphPad Software Inc., San
Diego, CA, USA) was used for analysis and representation.
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GluD1 KO mice have previously been described to be normal
in motor coordination, balance and spatial learning [10]. A
general observation we made with the GluD1 KO was their
uneasiness during regular human handling displayed by their
hypersensitivity to contact with the experimenter. We performed a
set of experiments to further test for locomotor activity, anxiety-
like behavior, depression- and aggression-like behaviors and social
interaction, in GluD1 KO mice. Moreover, we tested the effect of
lithium and DCS on the behavioral deficits in GluD1 KO.
GluD1 knockout mice exhibit greater spontaneous
activity
As a first step we assessed some of the sensory abilities in GluD1
KO since these may confound results obtained from other
behavioral tasks. We measured the olfaction ability for WT
(n=8) and GluD1 KO (n=7) and found no significant difference
between the two genotypes (unpaired t-test, P=0.7618, F=1.185).
GluD1 KO (n=6 for both WT and GluD1 KO mice) had normal
vision as seen from the results of the grip test for vision. We next
examined the spontaneous activity in an open field test. Compared
to the WT mice (n=22), GluD1 KO mice (n=21) displayed
higher spontaneous locomotor activity (Fig. 1A; unpaired t-test
with Welch’s correction, P=0.0002, F=5.226). Both genotypes
displayed habituation to the novel environment, as indicated by
gradual reduction in activity in a time-dependent manner (data
not shown). Additionally, we measured the time spent in the
central square of the open field arena which is a measure of
anxiety-like behavior. Mice displaying greater anxiety-like behav-
ior tend to spend greater time in the periphery of the open field
arena compared to the central square. GluD1 KO mice (n=7)
manifest a trend for spending greater time in the central field of
the open field arena compared to WT mice (n=8) (Fig. 1B;
unpaired t-test, P=0.0649, F=1.206).
GluD1 knockout mice exhibit lower anxiety-like behavior
Based on the results of the time spent in the central square of the
open field arena we found that GluD1 KO mice display a trend
for lower anxiety-like behavior. In order to further study anxiety-
like behavior, we conducted the marble burying test. GluD1 KO
mice (n=6) buried significantly fewer marbles compared to WT
mice (n=6) (Fig. 2A; unpaired t-test, P=0.0097, F=2.333). In
addition, in the elevated plus maze GluD1 KO mice (n=9) were
found to have significantly higher percent entries into the open
arms compared to WT mice (n=7) (Fig. 2B; unpaired t-test with
Welch’s correction, P=0.0093, F=4.621) and GluD1 KO mice
(n=9) spent significantly greater percent time in the open arms
compared to WT mice (n=7) (Fig. 2B; unpaired t-test with
Welch’s correction, P=0.0027, F=5.746). Although the param-
eter of number of entries may be confounded by hyperactivity
which was observed with GluD1 KO in the open field test, overall
these results suggest that GluD1 KO mice manifest lower anxiety-
like behavior.
GluD1 knockout mice exhibit depression-like behavior
We next tested depression-like behavior in WT and GluD1 KO
using the forced swim test. GluD1 KO mice (n=13) displayed a
significantly greater duration of immobility (Fig. 3A; unpaired t-
test, P,0.0001, F=1.060) compared to the WT (n=11) mice. In
addition, the latency was significantly shorter for GluD1 KO
compared to WT (Fig. 3B; unpaired t-test, P=0.0040, F=3.446).
Additionally we conducted the sucrose preference test to assess for
depression-like behavior in GluD1 KO mice. GluD1 KO mice
(n=5) manifested significantly lower preference for sucrose
compared to WT (n=7) mice (Fig. 3C; unpaired t-test, P=
0.0118, F=2.275).
GluD1 knockout mice exhibit aggression-like behavior
Another observation we made was that the GluD1 KO mice
displayed more home cage fights when group housed (data not
shown). Thus, in order to assess aggressive behavior in the GluD1
KO mice we conducted the resident-intruder test. The GluD1 KO
mice (n=12) attacked an intruder mouse with a significantly
higher frequency than WT mice (n=9) (Fig. 4A; unpaired t-test
with Welch’s correction, P=0.0003, F=6.577). GluD1 KO mice
on an average attacked the intruder mouse twelve times as
compared to the WT mice which attacked the intruder
approximately twice in the 10 min duration of the resident-
intruder test. In addition, GluD1 KO mice had a shorter latency
to attack compared to the WT mice (Fig. 4B; unpaired t-test,
P=0.0105, F=4.605).
Behavioral effects of chronic lithium treatment on GluD1
knockout mice
Cycling of mania and depression is a characteristic feature of
bipolar disorder for which the drug of choice is lithium [40–42].
Since, hyperaggression- and depression-like behavior in the GluD1
KO mirror some aspects of bipolar disorder, we tested the effect of
chronic lithium on these behaviors [43]. Four groups of mice,
control diet WT, lithium diet WT, control diet GluD1 KO and
lithium diet GluD1 KO were kept on a lithium treatment protocol
as described in the Methods. We first performed the open field test
(n=7–9 for each group). We found no drug X genotype effect in
the open field test (Fig. 5A; two-way ANOVA, drug F(1,
27)=0.8275, P=0.3710; genotype F(1, 27)=5.678, P=0.0245;
interaction F(1, 27)=2.589, P=0.1192). We next performed the
forced swim test (n=11–13 for each group). Lithium was effective
in normalizing the depression-like behavior as measured by
duration of immobility in the forced swim test (Fig. 5B; two-way
ANOVA, drug F(1, 43)=9.717, P=0.0033; genotype F(1,
43)=80.49, P,0.0001; interaction F(1, 43)=15.84, P=0.0003).
Thus lithium was able to rescue depression-like behavior in GluD1
KO. Further we performed the resident-intruder test using a
different set of animals (n=5–6 for each group). Lithium was not
Figure 1. GluD1 KO have higher spontaneous activity. A. GluD1
KO mice (n=21) displayed increased spontaneous locomotor activity in
the 15 min open field test compared to the WT mice (n=22) (unpaired
t-test with Welch’s correction, P=0.0002, F=5.226). B. GluD1 KO mice
(n=7) display a trend to spend greater time in the central field of the
open field arena compared to WT mice (n=8) (unpaired t-test,
P=0.0649, F=1.206). Data are presented as mean 6 SEM.
*** represents P,0.001.
doi:10.1371/journal.pone.0032969.g001
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of attacks (Fig. 5C; two-way ANOVA, drug F(1, 17)=0.3570,
P=0.5581; genotype F(1, 17)=17.12, P=0.0007; interaction F(1,
17)=0.9182, P=0.3514).
GluD1 knockout mice exhibit behavioral abnormalities in
social interaction and D-Cycloserine rescues the social
interaction deficit in GluD1 knockout mice
GRID1 gene is strongly associated with schizophrenia and
ASD, disorders that are characterized by social deficits [44–47].
Therefore we next tested whether GluD1 KO exhibit social
interaction deficits. We performed the sociability test as
previously described [37,38]. Figure 6A depicts a picture of the
social interaction chamber with the experimental and stranger
mice. In the test of social approach, where the mice chooses to
explore either an empty container or a container with a
conspecific mouse (Stranger 1), the WT mice (n=6) spent more
time interacting with Stranger 1 compared to the empty
container (Fig. 6B). This is in accordance with a preference of
a WT mouse for social interaction [48]. However, GluD1 KO
mice (n=7) spent almost the same time around the container
with the Stranger 1 or the empty container suggesting that GluD1
KO have a deficit in social interaction (Fig. 6B). There was a
significant difference in the percent time interacting with
Stranger 1 in WT and GluD1 KO (Fig. 6B; unpaired t-test,
P=0.0215, F=9.851). In the test for social novelty where a
second mouse (Stranger 2) was introduced into the empty
container there was no significant difference in the percent time
spent interacting with Stranger 2 in WT and GluD1 KO mice
(Fig. 6C; unpaired t-test, P=0.2420, F=1.904).
DCS is an NMDA receptor GluN1 subunit agonist [49] that has
shown efficacy in social interaction behaviors in rodents and social
impairment in humans [28,50,51]. We therefore tested the effect
of DCS on the social deficits in GluD1 KO mice. WT and GluD1
KO mice were intraperitoneally injected with DCS (320 mg/kg)
or saline 20 min prior to sociability test (n=6 for each group).
Remarkably, DCS administration in GluD1 KO significantly
enhanced percent time spent interacting with Stranger 1
Figure 2. GluD1 KO manifest lower anxiety-like behavior. A. GluD1 KO mice (n=6) buried significantly fewer marbles compared to WT mice
(n=6) (unpaired t-test, P=0.0097, F=2.333). B. GluD1 KO mice (n=9) made significantly higher percent entries into the open arms compared to WT
mice (n=7) (unpaired t-test with Welch’s correction, P=0.0093, F=4.621). C. GluD1 KO mice (n=9) spent significantly greater percent time in the
open arms compared to WT mice (n=7) in the elevated plus maze test (unpaired t-test with Welch’s correction, P=0.0027, F=5.746). Data are
presented as mean 6 SEM. ** represents P,0.01.
doi:10.1371/journal.pone.0032969.g002
Figure 3. GluD1 KO exhibit depression-like behavior. A. In a forced swim test GluD1 KO (n=13) displayed a greater duration of immobility
compared to WT mice (n=11) (unpaired t-test, P,0.0001, F=1.060). B. GluD1 KO (n=13) had a significantly shorter latency to immobility compared
to WT mice (n=11) (unpaired t-test, P=0.0040, F=3.446). C. GluD1 KO mice (n=5) manifested significantly lower preference for sucrose compared to
WT (n=7) mice (unpaired t-test, P=0.0118, F=2.275). Data are presented as mean 6 SEM. *** represents P,0.001 and ** represents P,0.01 and
* represents P,0.05.
doi:10.1371/journal.pone.0032969.g003
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drug F(1, 20)=34.28, P,0.0001; genotype F(1, 20)=2.103,
P=0.1625; interaction F(1, 20)=44.79, P,0.0001). In the test
of social novelty, DCS administered GluD1 KO showed
significantly higher percent time interacting with Stranger 2
compared to Stranger 1 (Fig. 7B; two-way ANOVA, drug F(1,
20)=3.897, P=0.0624; genotype F(1, 20)=5.811, P=0.0257;
interaction F(1, 20)=29.66, P,0.0001). Additionally, a small
group of GluD1 KO mice, that received a single dose of DCS
(320 mg/kg) were retested after 2 weeks of the first test and
demonstrated normal social interaction (data not shown). This
data suggests that a single dose of DCS may have long lasting
effects. Of note, the differences in the values for the saline treated
mice (Fig. 7A, B) versus naı ¨ve mice (Fig. 6B) in the social
interaction test may arise due to the injection stress.
Molecular abnormalities in the amygdala and prefrontal
cortex of GluD1 knockout mice and effect of D-
Cycloserine
Next we determined if expression of other iGluR subunits and
synaptic proteins is altered in the GluD1 KO mice. We specifically
tested changes in amygdala and prefrontal cortex of GluD1 KO
since these regions have been shown to regulate social and
emotional behaviors [52–55] . As a first step we performed RT-
PCR to determine expression of GluD1 signal in amygdala and
prefrontal cortex. GluD1 mRNA could be detected in both
amygdala and prefrontal cortex by RT-PCR, in addition to
hippocampus which is the primary site for GluD1 expression
[1,10] (Fig. 8A). Synaptoneurosomes were collected for 5–11
animals each for WT and GluD1 KO. We tested the effect of
deletion of GluD1 on a set of proteins representative of; (1) iGluR
subunits: GluA1, GluA2, GluK2, GluN2B; (2) presynaptic and
postsynaptic proteins: synaptophysin and PSD95 respectively and
(3) excitatory and inhibitory neurons: vGluT2 and GAD67
respectively. In the amygdala we found a significantly higher
expression of GluA1 (P=0.0486), GluK2 (P=0.0327) and PSD95
(P=0.0028) and a trend for higher expression of GAD67
(P=0.0640) in GluD1 KO (Fig. 8B, Table 1). A significantly
lower expression of GluA1 (P,0.001) and GluA2 (P=0.0345) was
observed in the prefrontal cortex of GluD1 KO (Fig. 8B, Table 1).
These results suggest that deletion of GluD1 leads to significant
changes in the expression of synaptic proteins which are crucial for
both excitatory and inhibitory synaptic neurotransmission.
We further tested whether the effect of DCS on social
interaction deficit is mediated by normalization of altered synaptic
proteins. We focused on GluA1 expression since this was altered in
both amygdala and prefrontal cortex. Synaptoneurosomes were
prepared from amygdala and prefrontal cortex, 2 hours after the
end of social novelty test in which saline or DCS (320 mg/kg) was
administered (n=3 for each group). As seen in Fig. 9, DCS did not
normalize the higher GluA1 expression in amygdala (Fig. 9, two-
way ANOVA, drug F(1,8)=0.7175, P=0.4216; genotype F(1,8)
=35.59, P=0.0003; interaction F(1,8)=0.2622, P=0.6224).
Figure 4. GluD1 KO are hyperaggressive. A. In the resident-
intruder test for aggression GluD1 KO mice (n=12) manifested robust
aggression with a higher attack frequency compared to WT mice (n=9)
(attack frequency, unpaired t-test with Welch’s correction, P=0.0003,
F=6.577). B. GluD1 KO mice (n=12) have a significantly shorter attack
latency compared to WT mice (n=9) (unpaired t-test, P=0.0105,
F=4.605). Data are presented as mean 6 SEM. *** represents P,0.001
and * represents P,0.05.
doi:10.1371/journal.pone.0032969.g004
Figure 5. Lithium rescues depression-like behavior in GluD1 KO. A. Open field test was performed on four groups, control diet WT (n=7),
lithium WT (n=9), control diet GluD1 KO (n=8) and lithium GluD1 KO (n=7). In the open field test no drug X genotype effect was observed in the
number of line crossings (two-way ANOVA, drug F(1, 27)=0.8275, P=0.3710; genotype F(1, 27)=5.678, P=0.0245; interaction F(1, 27)=2.589,
P=0.1192). B. Forced swim test was performed on control diet WT (n=12), lithium WT (n=13), control diet GluD1 KO (n=11) and lithium GluD1 KO
(n=11). Lithium reduced the immobility time in forced swim test in the GluD1 KO (two-way ANOVA, drug F(1, 43)=9.717, P=0.0033; genotype F(1,
43)=80.49, P,0.0001; interaction F(1, 43)=15.84, P=0.0003). C. Resident-intruder test was performed on control diet WT (n=5), lithium WT (n=5),
control diet GluD1 KO (n=6) and lithium GluD1 KO (n=5). Lithium failed to rescue the higher attack frequency in GluD1 KO in the resident-intruder
test (attack frequency: two-way ANOVA, drug F(1, 17)=0.3570, P=0.5581; genotype F(1, 17)=17.12, P=0.0007; interaction F(1, 17)=0.9182,
P=0.3514). Data are presented as mean 6 SEM. *** represents P,0.001.
doi:10.1371/journal.pone.0032969.g005
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PLoS ONE | www.plosone.org 7 March 2012 | Volume 7 | Issue 3 | e32969Figure 6. GluD1 KO exhibit a deficit in social interaction. A. The social interaction chamber with the experimental and stranger mice. B. In the
sociability test GluD1 KO mice (n=7) spent less percent time interacting with the Stranger 1 (unpaired t-test, P=0.0215, F=9.851) compared to WT
mice (n=6). C. In the test for social novelty where a second stranger (Stranger 2) mouse was introduced into the empty container there was no
significant difference in the percent time spent interacting with Stranger 2 in WT and GluD1 KO mice (unpaired t-test, P=0.2420, F=1.904). Data are
presented as mean 6 SEM. * represents P,0.05.
doi:10.1371/journal.pone.0032969.g006
Figure 7. DCS rescues social interaction deficits in GluD1 KO. A. WT and GluD1 KO mice were intraperitoneally injected with DCS (320 mg/
kg) or saline 20 min prior to sociability test (n=6 for each group). DCS administration in GluD1 KO significantly enhanced percent time spent
interacting with Stranger 1 compared to the empty container (two-way ANOVA, drug F(1, 20)=34.28, P,0.0001; genotype F(1, 20)=2.103, P=0.1625;
interaction F(1, 20)=44.79, P,0.0001). B. In the test of social novelty GluD1 KO showed significantly higher percent time interacting with Stranger 2
compared to Stranger 1 (two-way ANOVA, drug F(1, 20)=3.897, P=0.0624; genotype F(1, 20)=5.811, P=0.0257; interaction F(1, 20)=29.66,
P,0.0001). Data are presented as mean 6 SEM. *** represents P,0.001.
doi:10.1371/journal.pone.0032969.g007
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increased to the WT levels by DCS treatment (Fig. 9, two-way
ANOVA, drug F(1,8)=11.57, P=0.0093; genotype F(1,8)=
5.884, P=0.0415; interaction F(1,8)=6.140, P=0.0382). These
results are in accordance with a potential role of glutamate
receptors in the prefrontal cortex in social behaviors [53,56,57].
Discussion
Among the ionotropic glutamate receptor family, GluD1 is the
least studied and its role in the CNS remains unknown. We have
identified a novel role of GluD1 whereby its deletion leads to
appearance of aberrant behaviors that mirror emotional and social
behaviors in patients with neuropsychiatric disorders. In particu-
lar, we observed that deletion of GluD1 led to hyperactivity, lower
anxiety-like behavior, depression- and aggression-like behavior
and social interaction deficits. These deficits were partially rescued
by treatment with lithium and D-Cycloserine (DCS). Since
amygdala and prefrontal cortex have been implicated in these
emotional and social behaviors [52,58–61], we hypothesized that
GluD1 deletion may lead to abnormalities in these regions.
Indeed, we observed changes in the expression of synaptoneur-
osomal proteins in both amygdala and prefrontal cortex.
Behavioral abnormalities due to deletion of GluD1
One of the unique features of GluD1 knockout was the presence
of both depression- and aggression-like behaviors (Fig. 3, 4) which
mirror some features of bipolar disorder-like behavior. We
therefore tested whether lithium, a mood stabilizer, may be
effective in these behaviors. Lithium was effective in reducing
Figure 8. Altered expression of iGluR subunits and synaptic proteins in GluD1 KO. A. RT-PCR showed expression of the GluD1 mRNA in
the amygdala, hippocampus and the prefrontal cortex of P15 WT mice. No expression of GluD1 mRNA was seen in GluD1 KO. B. Synaptoneurosomes
were collected (5–11 animals each for WT and GluD1 KO) and western blotting analysis was performed for iGluR subunits and synaptic proteins. In
synaptoneurosomal preparations from the amygdala of GluD1 KO and WT mice we found a significantly higher expression of GluA1 (P=0.0486),
GluK2 (P=0.0327) and PSD95 (P=0.0028) and a trend for higher expression of GAD67 (P=0.0640) in GluD1 KO. In the prefrontal cortex we observed a
significantly lower expression of GluA1 (P,0.001) and GluA2 (P=0.0345) in GluD1 KO. Data are presented as mean 6 SEM. *** represents P,0.001,
** represents P,0.01 and * represents P,0.05.
doi:10.1371/journal.pone.0032969.g008
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However, lithium was ineffective in hyperactivity (Fig. 5A) and
aggression-like behavior in the resident-intruder test (Fig. 5C). We
also observed significant deficits in the sociability test in the GluD1
knockout which were rescued by DCS treatment (Fig. 6B, 7A, B).
DCS has been shown to improve impaired sociability in Balb/c
mice [28] and enhance pair bonding in prairie voles [50]. In
humans, DCS has also been found to improve social withdrawal in
autistic patients [51] and enhance exposure therapy in social
anxiety disorder [62,63]. Our study is in agreement with this
growing body of evidence that DCS may be effective in treating
social interaction deficits. At the molecular level we found that
DCS reversed the lower GluA1 expression in the prefrontal cortex
but did not normalize the higher GluA1 expression in amygdala
(Fig. 9). These data suggest that the effect of DCS on social
interaction behavior may be mediated by affecting signaling in the
prefrontal cortex. DCS is an agonist at the NMDA receptor and its
efficacy, in comparison to endogenous agonists’ glycine and D-
serine is GluN2 subtype dependent. Specifically, DCS is a partial
agonist with ,60% efficacy at GluN2B receptors but acts as a full
agonist at other GluN2 subtypes [49,64]. Thus, one possibility is
that the effect of DCS in GluD1 knockout on social interaction
and GluA1 expression in the prefrontal cortex may arise due to the
inhibition of GluN2B receptors. This hypothesis is in agreement
with a recent study demonstrating that administration of a specific
GluN2B inhibitor elevates GluA1 expression and leads to
synaptogenesis in the prefrontal cortex [65]. It will therefore be
of interest to test whether deletion of GluD1 leads to abnormal
synaptogenesis in the prefrontal cortex and whether this can be
rescued by DCS or GluN2B inhibitors.
We also found that GluD1 heterozygous mice when tested in
the forced swim test had significantly higher immobility time (data
not shown). These results further suggest that GluD1 subunit plays
a non-redundant function in the CNS and the presence of both
copies of GluD1 is necessary for normal behavior. Thus, lower
expression of GluD1 may act as a predisposing factor for
neuropsychiatric disorders. Interestingly, lower GluD1 expression
has been reported in the cortex of human patients with
schizophrenia, bipolar disorder and ASD [18,66]. Additionally,
in a chronic mild stress model of depression-like behavior in rats,
GluD1 mRNA in the frontal cortex is downregulated and this
could be completely reversed by the antipsychotic quetiapine
[20,21].
Abnormalities in the expression of synaptoneurosomal
proteins by GluD1 deletion
The potential mechanism for changes in expression of iGluR
subunits in GluD1 knockout may be gleaned from studies on
GluD2 which is the closest homolog of GluD1. Specifically, we
observed abnormalities in the expression of GluA1, GluA2 and
GluK2 which have all been shown to either directly interact with
GluD2 forming a heteromer or are regulated during surface
trafficking by GluD2 [67–69]. Thus it is conceivable that GluD1
may similarly be crucial in regulation of these iGluR subunits in
the amygdala and prefrontal cortex. We also observed higher
Table 1. Synaptic protein composition in GluD1 KO mice.
Protein Amygdala Prefrontal Cortex
Ratio SEM P Ratio SEM P
GluA1 2.293 0.563 0.0486* 0.508 0.056 ,0.001***
GluA2 0.885 0.115 0.5686 0.528 0.198 0.0345*
GluN2B 1.180 0.152 0.2780 1.770 0.478 0.1364
GluK2 1.764 0.286 0.0327* 0.930 0.060 0.4428
vGluT2 1.087 0.258 0.7556 1.059 0.277 0.8747
GAD67 1.269 0.111 0.0640 0.941 0.207 0.8027
PSD95 1.601 0.146 0.0028** 1.286 0.237 0.2761
Synaptophysin 1.166 0.118 0.2905 1.049 0.196 0.8176
Synaptoneurosomes were isolated from the GluD1 KO and WT amygdala and
prefrontal cortex and western blotting was performed (5–11 animals for each
group). Data are presented as mean 6 SEM. First, the optical density of each
sample was normalized to b-actin. Thereafter, the optical density was
normalized to the mean of the WT samples. The average 6 SEM of optical
densities of GluD1 KO samples, that were normalized to WT mean, are
represented as Ratio (KO/WT) 6 SEM. The P values were calculated from optical
densities of WT and GluD1 KO samples normalized to the WT mean.
***represents P,0.001.
**represents P,0.01 and.
*represents P,0.05.
doi:10.1371/journal.pone.0032969.t001
Figure 9. DCS normalized the reduced GluA1 expression in prefrontal cortex in GluD1 KO. Synaptoneurosomes were prepared from
amygdala and prefrontal cortex 2 hours after the end of the social novelty test in which saline or DCS (320 mg/kg) was administered intraperitoneally
(Fig. 7) (n=3 for each group). GluA1 expression was higher in GluD1 KO amygdala and lower in the prefrontal cortex. DCS did not normalize the
higher GluA1 expression in amygdala (two-way ANOVA, drug F(1,8)=0.7175, P=0.4216; genotype F(1,8)=35.59, P=0.0003; interaction
F(1,8)=0.2622, P=0.6224). In the prefrontal cortex the lower GluA1 expression was increased to the WT levels by DCS treatment (two-way
ANOVA, drug F(1,8)=11.57, P=0.0093; genotype F(1,8)=5.884, P=0.0415; interaction F(1,8)=6.140, P=0.0382). Data are presented as mean 6 SEM.
* represents P,0.05.
doi:10.1371/journal.pone.0032969.g009
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correlates with elevated PSD95 reported in lateral amygdala in
patients suffering from depression [70]. Both the amygdala and
prefrontal cortex have been implicated in major depression [71–
77]. Additionally, changes in synaptic proteins and glutamate
neurotransmission in the amygdala and prefrontal cortex are
associated with depression [70,78–81]. We also observed a trend
for higher GAD67, a marker for inhibitory neurons, in the
amygdala. This suggests a potential dysregulation of both
excitatory and inhibitory synapses in the GluD1 knockout.
Interestingly, excitatory-inhibitory imbalance in prefrontal cortex
and amygdala have been reported in schizophrenia and ASD
animal models [82–84], disorders with which GluD1 has been
associated.
Another unique feature of the protein expression study was the
opposing effects in the expression of a-amino-3-hydroxy-5-methyl-
4-isoxazolepropionic acid receptor (AMPA) and kainate subunits
in amygdala versus prefrontal cortex. Broadly, there was an
upregulation of expression in the amygdala and a downregulation
in prefrontal cortex. Moreover, DCS selectively normalized
GluA1 expression in the prefrontal cortex and lithium rescued
depression-like behavior but not hyperactivity and aggression like
behavior. These results suggest that deletion of GluD1 may have
unique and contrasting effects on synapses in different brain
regions which likely lead to these unique arrays of behavioral
anomalies. Future electrophysiological and structural studies will
be required to address the ability of GluD1 to selectively modify
neural circuitry in different brain regions.
One of the shortcomings in our molecular studies is that we did
not analyze other regions in the brain that may be involved in
emotional or social behaviors, a prominent one being the
hippocampus. Decreased hippocampal volume and moderate
apoptosis has been reported in the hippocampus in patients with
major depression [67–74]. Additionally, aggressive behavior
results in reduction in hippocampal volume [75,76]. The
hippocampus also has a role in social behaviors. Hippocampal
lesions in rodents lead to abnormal social behavior and social
interaction [77–79]. Studies in humans have also reported
differential activity in neurons within the hippocampal formation
during presentation of social cues [80–82]. The hippocampus also
has a role in anxiety-like behavior [83,84]. On a molecular level
post-mortem studies have reported a decrease in AMPA and
kainate receptor expression in the hippocampus in schizophrenia,
bipolar disorder and major depression [85–91]. Studies using
mouse models have demonstrated a role of AMPA receptors in the
hippocampus in mania- and depression-like behavior [92,93]. In
addition, GluK2 knockout mice exhibit mania-like behavior along
with lower GluK1 receptor expression in the hippocampus [27].
Thus, abnormalities in hippocampal function and changes in
AMPA/kainate expression in the hippocampus may be involved in
the pathophysiology of certain types of mental disorders and
behavioral abnormalities similar to those observed in GluD1
knockout. Given that GluD1 is highly expressed in the
hippocampus it is possible that deletion of GluD1 may lead to
synaptic abnormalities including changes in AMPA/kainate
receptor expression in the hippocampus. Further studies are
therefore necessary to delineate the role of hippocampus in the
behavioral abnormalities observed in GluD1 knockout. Addition-
ally, since the pharmacology of GluD1 is poorly understood [85],
the best tool to study the brain region-specific role of GluD1 would
be through selective genetic manipulations.
GluD1 dysfunction and relevance to synaptic theory of
mental disorders
As previously stated, the GRID1 gene that codes for GluD1 is
strongly associated with mental disorders including schizophrenia,
bipolar disorder, ASD and major depression [14–26,94–96]. Our
behavioral studies in GluD1 knockout further strengthens the idea
that dysfunction of GluD1 may lead to behavioral deficits. A
growing body of evidence suggests that disorders like schizophre-
nia, bipolar disorder and ASD which show genetic overlap [97]
involve synaptic abnormalities that predispose individuals to these
conditions. Mutations affecting a number of synaptic proteins have
been observed in schizophrenia, bipolar disorder and ASD [98–
103]. GluD1 is developmentally expressed and has been shown to
affect presynaptic differentiation and synapse formation in in vitro
systems [8]. Additionally, abundant data exists on the role of
GluD2, which is the closest homolog of GluD1, in synapse
formation [5,6,8,67]. Moreover, it was recently shown that
postsynaptic GluD2 interacts with presynaptic neurexin1 via
cerebellin 1 protein [13] and a similar interaction may occur with
GluD1. This finding is particularly interesting since mutations in
neurexins are well known to be associated particularly with
schizophrenia and ASD [22,104–106]. These converging human
genetic and molecular studies on GluD1 together with our results
suggest that GluD1 might be a synaptic protein whose dysfunction
may lead to abnormal synapse formation or function which
predisposes individuals to neuropsychiatric conditions. Indeed
further experiments are required to identify a specific role of
GluD1 in the regulation of synaptic structure or function.
Moreover, these novel roles may provide valuable insights into
the regulation of behaviors relevant to neuropsychiatric disorders.
Animal models for mood disorders and other mental disorders
are important for exploring the pathophysiology of human disease
and for development of treatments. Animal models exhibiting
spontaneously alternating mania- and depression-like behaviors
for bipolar disorder are not known [107]. Among the prevailing
models for bipolar disorder are overexpression of glycogen
synthase kinase 3 beta (GSK3 beta) [108] and clock mutant
[109]. Interestingly, the occurrence of both mania- and depres-
sion-like behaviors suggests that GluD1 knockout may have some
face validity for bipolar-like behavior. Additionally lithium was
able to rescue the depression-like behavior in GluD1 knockout
suggesting that the model may have some predictive validity.
Further studies will however be required to address whether there
is any altering pattern of behaviors and to further establish
predictive and construct validity. It is also possible that the
behavior exhibited by GluD1 knockout may relate more closely to
other mental disorders specifically ASDs and further detailed
studies will be required to test this hypothesis.
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